Ikena Oncology Revenue 2021-2025 | IMA
Ikena Oncology revenue from 2021 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Ikena Oncology Annual Revenue
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$9 |
| 2022 |
$16 |
| 2021 |
$31 |
| 2020 |
$9 |
Ikena Oncology Quarterly Revenue
(Millions of US $) |
| 2025-03-31 |
|
| 2024-12-31 |
|
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$2 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$5 |
| 2022-09-30 |
$6 |
| 2022-06-30 |
$0 |
| 2022-03-31 |
$3 |
| 2021-12-31 |
$20 |
| 2021-09-30 |
$4 |
| 2021-06-30 |
$4 |
| 2021-03-31 |
$3 |
| 2020-12-31 |
$0 |
| 2020-09-30 |
$3 |
| 2020-06-30 |
$3 |
| 2020-03-31 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.061B |
$0.009B |
|
Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company's product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States.
|
